CGP-37849
Clinical data
Other namesCGP-37849, CGP-40116
Identifiers
  • (E,2R)-2-amino-4-methyl-5-phosphonopent-3-enoic acid
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC6H12NO5P
Molar mass209.138 g·mol−1
3D model (JSmol)
  • C/C(=C\[C@H](C(=O)O)N)/CP(=O)(O)O
  • InChI=1S/C6H12NO5P/c1-4(3-13(10,11)12)2-5(7)6(8)9/h2,5H,3,7H2,1H3,(H,8,9)(H2,10,11,12)/b4-2+/t5-/m1/s1 ☒N
  • Key:BDYHNCZIGYIOGJ-XWCPEMDWSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

CGP-37849 is a competitive antagonist at the NMDA receptor.[1] It is a potent, orally active anticonvulsant in animal models,[2] and was researched for the treatment of epilepsy.[3] It also has neuroprotective activity[4] and shows antidepressant[5][6] and anxiolytic effects.[7][8]

References

  1. ↑ Fagg GE, Olpe HR, Pozza MF, Baud J, Steinmann M, Schmutz M, et al. (April 1990). "CGP 37849 and CGP 39551: novel and potent competitive N-methyl-D-aspartate receptor antagonists with oral activity". British Journal of Pharmacology. 99 (4): 791–7. doi:10.1111/j.1476-5381.1990.tb13008.x. PMC 1917531. PMID 1972895.
  2. ↑ Schmutz M, Portet C, Jeker A, Klebs K, Vassout A, Allgeier H, et al. (July 1990). "The competitive NMDA receptor antagonists CGP 37849 and CGP 39551 are potent, orally-active anticonvulsants in rodents". Naunyn-Schmiedeberg's Archives of Pharmacology. 342 (1): 61–6. doi:10.1007/bf00178973. PMID 1976233. S2CID 25531153.
  3. ↑ Fujikawa DG, Daniels AH, Kim JS (March 1994). "The competitive NMDA receptor antagonist CGP 40116 protects against status epilepticus-induced neuronal damage". Epilepsy Research. 17 (3): 207–19. doi:10.1016/0920-1211(94)90051-5. PMID 7912191. S2CID 13656613.
  4. ↑ Gutnikov SA, Gaffan D (June 1996). "Systemic NMDA receptor antagonist CGP-40116 does not impair memory acquisition but protects against NMDA neurotoxicity in rhesus monkeys". The Journal of Neuroscience. 16 (12): 4041–5. doi:10.1523/JNEUROSCI.16-12-04041.1996. PMC 6578604. PMID 8656297.
  5. ↑ Maj J, Klimek V, Gołembiowska K, Rogóz Z, Skuza G (1993). "Central effects of repeated treatment with CGP 37849, a competitive NMDA receptor antagonist with potential antidepressant activity". Polish Journal of Pharmacology. 45 (5–6): 455–66. PMID 7912134.
  6. ↑ Papp M, Moryl E (September 1994). "Antidepressant activity of non-competitive and competitive NMDA receptor antagonists in a chronic mild stress model of depression". European Journal of Pharmacology. 263 (1–2): 1–7. doi:10.1016/0014-2999(94)90516-9. PMID 7821340.
  7. ↑ Jessa M, Nazar M, Bidzinski A, Plaznik A (March 1996). "The effects of repeated administration of diazepam, MK-801 and CGP 37849 on rat behavior in two models of anxiety". European Neuropsychopharmacology. 6 (1): 55–61. doi:10.1016/0924-977x(95)00068-z. PMID 8866939. S2CID 45953054.
  8. ↑ Przegaliński E, Tatarczyńska E, Chojnacka-Wójcik E (July 2000). "The influence of the benzodiazepine receptor antagonist flumazenil on the anxiolytic-like effects of CGP 37849 and ACPC in rats". Neuropharmacology. 39 (10): 1858–64. doi:10.1016/s0028-3908(00)00023-x. PMID 10884566. S2CID 33660694.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.